drugset / Trial / NCT04220411
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.
Timeline
- Start
- 2020-12-08
- Primary completion
- 2021-12-29
- Completion
- 2022-06-13
Outcome
Outcome not reported
Stopped (Enrollment): “Due to the two AEs in Phase IIa study, recruiting was stopped for safety sake. The study was currently terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OVATODIOLIDE | Small molecule | 1.25 % | Topical |
| Subject | OVATODIOLIDE | Small molecule | 2.5 % | Topical |
| Subject | OVATODIOLIDE | Small molecule | 5 % | Topical |